Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025)

Benitec Biopharma has reported Return on Capital Employed over the past 6 years, most recently at 27.15% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 27.15% for Q4 2025, down 220.0% from a year ago — trailing twelve months through Dec 2025 was 27.15% (down 220.0% YoY), and the annual figure for FY2025 was 56.36%, up 3969.0%.
  • Return on Capital Employed reached 27.15% in Q4 2025 per BNTC's latest filing, up from 28.17% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 21.95% in Q1 2025 and bottomed at 807.15% in Q2 2023.
  • Median Return on Capital Employed over the past 5 years was 111.27% (2021), compared with a mean of 150.76%.
  • The largest annual shift saw Return on Capital Employed plummeted -48171bps in 2023 before it surged 72873bps in 2024.
  • Over 5 years, Return on Capital Employed stood at 128.71% in 2021, then dropped by -14bps to 146.86% in 2022, then rose by 20bps to 117.53% in 2023, then soared by 79bps to 24.95% in 2024, then dropped by -9bps to 27.15% in 2025.
  • Business Quant data shows Return on Capital Employed for BNTC at 27.15% in Q4 2025, 28.17% in Q3 2025, and 22.83% in Q2 2025.